Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 13, 2021 at 06:32 pm IST
Share
Inhibitor Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 62,635 compared to USD 315,044 a year ago. Net loss was USD 66,182 compared to USD 314,894 a year ago. For the half year, operating loss was USD 230,388 compared to USD 700,486 a year ago. Net loss was USD 194,020 compared to USD 699,311 a year ago.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.